| 楚晨龙 周文龙 赵晨晖 黄滔 张志伟 王名伟 杨安卿 马斌斌 忻志祥.培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究[J].,2016,16(15):2864-2867 |
| 培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究 |
| The Efficacy and Safety of Pemetrexed plus Cisplatin on Patients withAdvanced Urothelial Carcinoma |
| |
| DOI： |
| 中文关键词: 尿路上皮癌 培美曲塞 疗效 |
| 英文关键词: Urothelial carcinoma Pemetrexed Efficacy |
| 基金项目:上海市黄浦区卫生系统重点学科建设项目（PWZXK2011-18） |
|
| 摘要点击次数: 1109 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评估培美曲塞联合顺铂治疗晚期尿路上皮癌的有效性和安全性。方法：纳入在我院泌尿科治疗的65 例晚期上皮癌患
者。每隔3 周为患者注射培美曲塞500 mg·m-2，顺铂70 mg·m-2。试验主要终点为客观缓解率（ORR），次要终点为无疾病进展期
（PFS）、总生存期（OS）和毒性。采用Kaplan-Meier 法计算生存率。结果：患者客观响应率为65.4%（95%CI：50.3%-78.1%），42 例患
者有部分缓解，11 例患者疾病稳定。PFS和OS分别为7.1（95%CI：6.3-8.7）个月与15.5 个月（95%CI：11.5-19.5）个月。29.2%的患
者出现3 级或4 级嗜中性白血球减少症，无发热性中性粒细胞减少情况出现。结论：培美曲塞联合顺铂用于晚期尿路上皮癌一线
治疗十分有效，且耐受性良好。 |
| 英文摘要: |
| Objective:To evaluate the efficacy and safety of patients with advanced urothelial carcinoma treated by pemetrexed
plus cisplatin.Methods:A total of 65 patients with advanced epithelial cancer in our hospital were included. The patients were injected
with 500 mg·m-2 pemetrexed and 70 mg·m-2 cisplatin at every fouth week. The primary endpoint for the trial objective was response rate
(ORR). The secondary endpoint were progression-free (PFS), overall survival (OS) and toxicity. Survival rate was calculated using the
Kaplan-Meier method.Results:The objective response rate of patients was 65.4%(95%CI: 50.3%-78.1%). Fourty-two patients had partial
remission, and 11 patients had disease stable. The PFS and OS were respectively 7.1 months (95% CI: 6.3-8.7) and 15.5 months
(95%CI: 11.5-19.5). There were 29.2%of patients with grade 3 or 4 neutropenia disease, and no febrile neutropenia situation appeared.Conclusion:Pemetrexed in combination with cisplatin is very effective and well tolerated in the first-line treatment of advanced urothelial
cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
